BioCryst Pharma (BCRX) PT Raised to $16 at RBC Capital; Sees Continued Upside

December 4, 2018 6:39 AM EST Send to a Friend
RBC Capital analyst Brian Abraham raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $16.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login